

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Atty. Dkt. No.

Client Matter No.

Client Ref.

044137-5025

Applicant: Alan SOLOMON *et al.*

Appln. No.: 09/316,387

Filing Date: May 21, 1999

Examiner: S. Turner

Group Art Unit: 1647

Date: October 23, 2002

Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						

FOREIGN PATENT DOCUMENTS

CREATOR					Available					
		Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclose	No
	FR									
	GR									
	HR									
	IR									
	JR									
Country (Denmark etc.)										

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

KR	Holmgren <i>et al.</i> , Lancet, Vol. 341, May 1, 1993, pp. 1113-1116
LR	Kuo <i>et al.</i> , "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains", The Journal of Biological Chemistry, Vol. 271, No. 8, Feb. 23, 1996, pp. 4077-4081
MR	Schehr, "Therapeutic Approaches to Alzheimer's Disease", Bio/Technology, Vol. 12, Feb. 1994, pp. 140-144
NR	Grubeck-Loebenstein <i>et al.</i> , "Immunization with β -amyloid: could T-cell activation have a harmful effect?", TINS, Vol. 23, No. 3, 2000, pp. 11
OR	Lee, "A β immunization: Moving A β peptide from brain to blood", PNAS, Vol. 98, No. 16, July 31, 2001, pp. 8931-8932
PR	Shenk <i>et al.</i> , "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse", Nature, Vol. 400, July 8, 1999, pp. 173-177
QR	Falk <i>et al.</i> , "The Systemic Amyloidoses", The New England Journal of Medicine, Vol. 337, No. 13, Sept. 25, 1997, pp. 898-908
RR	Tjernberg <i>et al.</i> , "Arrest of β -Amyloid Fibril Formation by a Pentapeptide Ligand", The Journal of Biological Chemistry, Vol. 271, No. 15, April 12, 1996, pp. 8545-8548
SR	Kisilevsky, "Anti-Amyloid Drugs - Potential in the Treatment of Diseases Associated with Aging", Drugs & Aging, Vol. 8, No. 2, Feb., 1996, pp. 75-83
TR	

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.